Compass Therapeutics CMPX Stock
Compass Therapeutics Price Chart
Compass Therapeutics CMPX Financial and Trading Overview
| Compass Therapeutics stock price | 1.62 USD |
| Previous Close | 3.22 USD |
| Open | 3.2 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 3.2 - 3.3 USD |
| 52 Week Range | 1.81 - 5.65 USD |
| Volume | 283.95K USD |
| Avg. Volume | 345.27K USD |
| Market Cap | 414.94M USD |
| Beta (5Y Monthly) | 0.368305 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.33 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.17 USD |
CMPX Valuation Measures
| Enterprise Value | 234.4M USD |
| Trailing P/E | N/A |
| Forward P/E | -6.9787235 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.3648162 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -5.404 |
Trading Information
Compass Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.368305 |
| 52-Week Change | 31.72% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.65 USD |
| 52 Week Low | 1.81 USD |
| 50-Day Moving Average | 3.13 USD |
| 200-Day Moving Average | 3.6 USD |
CMPX Share Statistics
| Avg. Volume (3 month) | 345.27K USD |
| Avg. Daily Volume (10-Days) | 305.65K USD |
| Shares Outstanding | 126.51M |
| Float | 98.28M |
| Short Ratio | 6.79 |
| % Held by Insiders | 15.66% |
| % Held by Institutions | 63.28% |
| Shares Short | 2.04M |
| Short % of Float | 2.25% |
| Short % of Shares Outstanding | 1.60% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -16.50% |
| Return on Equity (ttm) | -25.76% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -43373000 USD |
| Net Income Avi to Common (ttm) | -39900000 USD |
| Diluted EPS (ttm) | -0.36 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 175.17M USD |
| Total Cash Per Share (mrq) | 1.39 USD |
| Total Debt (mrq) | 2.64M USD |
| Total Debt/Equity (mrq) | 1.51 USD |
| Current Ratio (mrq) | 16.408 |
| Book Value Per Share (mrq) | 1.387 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -38412000 USD |
| Levered Free Cash Flow (ttm) | -23427000 USD |
Profile of Compass Therapeutics
| Country | United States |
| State | MA |
| City | Boston |
| Address | 80 Guest Street |
| ZIP | 02135 |
| Phone | 617 500 8099 |
| Website | https://www.compasstherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 26 |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Q&A For Compass Therapeutics Stock
What is a current CMPX stock price?
Compass Therapeutics CMPX stock price today per share is 1.62 USD.
How to purchase Compass Therapeutics stock?
You can buy CMPX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Compass Therapeutics?
The stock symbol or ticker of Compass Therapeutics is CMPX.
Which industry does the Compass Therapeutics company belong to?
The Compass Therapeutics industry is Biotechnology.
How many shares does Compass Therapeutics have in circulation?
The max supply of Compass Therapeutics shares is 137.59M.
What is Compass Therapeutics Price to Earnings Ratio (PE Ratio)?
Compass Therapeutics PE Ratio is now.
What was Compass Therapeutics earnings per share over the trailing 12 months (TTM)?
Compass Therapeutics EPS is -0.33 USD over the trailing 12 months.
Which sector does the Compass Therapeutics company belong to?
The Compass Therapeutics sector is Healthcare.
Compass Therapeutics CMPX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}